KBC Securities - Amoeba SA (AMEBA) Amoéba Capital increase to support its industrial and commercial rollout

Report

KBC Securities

Guy Sips

Amoéba Capital increase to support its industrial and commercial rollout

We updated our model (new € 1.5 Target Price, Buy) after Amoéba announced the closure of its capital increase to support its industrial and commercial rollout. Amoeba has therefore raised a gross amount of €14m, including €9m in cash contributed by institutional and individual investors, and €5m by offsetting receivables bringing the number of shares to 68.9m.

Amoéba indicated they now have sufficient financial resources to support its industrial and commercial growth and create value for its shareholders based on its expertise.
Total demand amounted to €14.5m, with 89% coming from institutional investors (including the guarantors of the transaction) and 11% from individual investors.
Nice & Green has subscribed for €8m, including €3m in cash and €5m in debt offset, and Koppert has subscribed for €0.8m.

The price per new share was €0.8105, corresponding to a discount of 20% compared to the last five trading days VWAP.

After the transaction Nice & Green holds 26.49%, management 3.02%, Koppert 1.43% and the Free float is 69.06%.

Amoéba announced, just before this transaction, the signing of an agreement with Metron Technology, a subsidiary of the Chinese group Oriental Beauty Valley (OBV group). Through this deal Amoéba accelerates the development of its cosmetic business.

24/07/2025 1 EN

Underlying

Amoeba SA

Amoeba SA. Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.

See profile

FR0011051598 Euronext Paris France

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Guy Sips

Other Reports on these Companies

KBC Securities

Amoéba Exemption from obligation to destroy trial crops in France

The French regulator ANSES has granted an exemption for Amoéba's biocontrol product Axpera, allowing crop trials without the usual requirement to destroy the harvest. This exemption, which applies to both open-field and greenhouse crops affected by various diseases, supports ongoing evaluations and follows recent regulatory milestones in France and the EU. While no material commercial sales are expected yet in 2025, the move is seen as another strong endorsement of Amoéba's innovative technology and a step closer to full market approval, reinforcing our confidence in the company's future poten...

June 25, 2025 June 25, 2025 1 EN

KBC Securities

Amoéba EU approval for Axpera's active substance

Amoéba has received final approval from the European Commission for the active substance of its biocontrol product, Axpera, marking it as a low-risk substance. This milestone concludes a five-year EU validation process and positions the company for commercialisation in Europe, with marketing authorisation applications underway in nine countries and decisions expected by late 2025/early 2026. We maintain a Buy rating with € 1.8 TP.

June 18, 2025 June 18, 2025 1 EN

Materialise Macro-economic uncertainty impacting business climate for 2H25

Although its Medical segment was demonstrating its resilience (nearly +17% y/y in 2Q25), Materialise's overall 2Q25 revenue decreased -5.8% y/y to € 64.8m impacted by increasing geo-political uncertainty and sustained macro-economic headwinds negatively impacted revenues in its Manufacturing and Software segments. Despite revenue pressure, Materialise was able to materially improve its operational profitability in 2Q25 q/q/ through structural and targeted cost control. Unfavourable FX-effects significantly impacted 2Q, but nevertheless Materialise again reported a small but positive net resu...

9h / 36m 9h / 36m 1 EN

Guy Sips ... (+7)

Guy Sips
Hilde Van Boxstael
Jacob Mekhael
Lynn Hautekeete
Michiel Declercq
Thomas Couvreur
Wim Lewi

Morning Notes : COFBb BB, ES6 BB, MTLS N US, PROXb BB, WPHB BB, PHVS US

: COFBb BB, ES6 BB, MTLS N US, PROXb BB, WPHB BB, PHVS US

11h / 21m 11h / 21m 1 EN

Wim Lewi

Wim Lewi

Elia Group 1H25 Results blow-out on German profit recognition items

The 1H25 trading update largely overshot our expectation with 269.3m, a 48.4% increase vs. our 223.8m expectation. This was mainly thanks to much better net profit at the 50Hz division that now benefits from a pro-rata profit recognition (+28.1m), higher capitalized interest (+16.6m) and a pre-financing agreement (+13.4m). ETB also came above our expectation and benefited from a 9.7m one-off compensation. Elia confirmed its FY25 outlook for Net Group Profit to Shareholders between EUR 490m and 540m. The outlook is now based on a 10y OLO of 3.1% vs. 2.8% previously and a 10y bund of 2.5% vs. 2....

11h / 36m 11h / 36m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Amoéba Capital increase to support its industrial and commercial rollout

We are a financial services provider for several types of professional clients, each with distinct needs.

Amoéba Exemption from obligation to destroy trial crops in France

Amoéba EU approval for Axpera's active substance

Materialise Macro-economic uncertainty impacting business climate for 2H25

Morning Notes : COFBb BB, ES6 BB, MTLS N US, PROXb BB, WPHB BB, PHVS US

Elia Group 1H25 Results blow-out on German profit recognition items

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe